Bausch + Lomb Announces FDA Filing AcceptanceFDA/Regulatory, Ocular Surgery, Ophthalmics, PDUFA, Post-operative eye painBausch + Lomb announced the U.S. FDA accepted the New Drug Application for the company’s sub-micron loteprednol etabonate ophthalmic gel 0.38% with a PDUFA date of Feb. 25, 2019. Read more July 9, 2018/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2018-07-09 08:00:202018-07-09 15:21:30Bausch + Lomb Announces FDA Filing Acceptance